Carcinoma Transitional Cell/*mortality/*pathology Humans Survival Rate Urinary Bladder Neoplasms/*mortality/*pathology carcinoma histology pathology survival transitional cell urinary bladder neoplasms

Disease-Free Survival *Dose Fractionation Radiation Humans Neoplasm Recurrence Local/epidemiology/pathology/*radiotherapy Radiation Dose Hypofractionation/*standards Risk Factors Treatment Outcome Urinary Bladder Neoplasms/epidemiology/pathology/*radiotherapy

Carcinoma Transitional Cell/mortality/surgery Cystectomy Disease-Free Survival Humans Nephroureterectomy Prognosis *Sex Factors Urinary Bladder Neoplasms/*mortality/*surgery Urologic Neoplasms/*mortality/*surgery carcinoma meta-analysis review [publication type] transitional cell urinary bladder neoplasms

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Clinical Trials as Topic Disease Progression Humans Neoplasm Metastasis *Neoplasm Recurrence Local Network Meta-Analysis Progression-Free Survival Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

Carcinoma Transitional Cell/*classification/*genetics/mortality Humans Predictive Value of Tests Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*classification/*genetics/mortality Bladder cancer Molecular classification Molecular subtype Prognosis Progression Urothelial carcinoma

Humans Lymphocytes/*pathology Neutrophils/*pathology *Preoperative Care Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*immunology/*surgery

Cystectomy/adverse effects/*methods Disease-Free Survival Follow-Up Studies Humans Incidence Intraoperative Complications/*epidemiology/etiology Length of Stay/statistics & numerical data Neoplasm Recurrence Local/*epidemiology/etiology/prevention & control Randomized Controlled Trials as Topic Urinary Bladder/*injuries/pathology/surgery Urinary Bladder Neoplasms/mortality/pathology/*surgery Bipolar bladder tumors meta-analysis monopolar transurethral resection

Cystectomy/*methods Humans Survival Analysis Urinary Bladder Neoplasms/mortality/*surgery Bladder cancer Delay Radical cystectomy Survival

Aged *Brachytherapy Combined Modality Therapy Disease-Free Survival Female Humans Male Middle Aged Neoplasm Recurrence Local *Urinary Bladder Neoplasms/mortality/pathology/radiotherapy external beam radiotherapy interstitial brachytherapy muscle-invasive bladder cancer organ preservation

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant/methods Cisplatin/therapeutic use Clinical Decision-Making/methods *Cystectomy Disease-Free Survival Female Humans Male Neoadjuvant Therapy/methods Neoplasm Recurrence Local/*epidemiology/pathology/prevention & control Neoplasm Staging Patient Selection *Sex Factors Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/mortality/pathology/*therapy Adjuvant chemotherapy Bladder cancer Gender Meta-analysis Neoadjuvant chemotherapy

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/immunology/mortality/pathology/*therapy Chemotherapy Adjuvant/methods/statistics & numerical data Clinical Trials Phase I as Topic Clinical Trials Phase II as Topic Cystectomy Disease-Free Survival Follow-Up Studies Humans Immune Checkpoint Inhibitors/*therapeutic use Muscle Smooth/pathology/surgery Neoadjuvant Therapy/*methods/statistics & numerical data Neoplasm Invasiveness/pathology Prospective Studies Treatment Outcome Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/immunology/mortality/pathology/*therapy Bladder cancer Immune checkpoint inhibitors Immunotherapy Neoadjuvant

Chemotherapy Adjuvant *Combined Modality Therapy Cystectomy Female Humans Middle Aged Muscles Neoadjuvant Therapy *Neoplasm Invasiveness Organ Sparing Treatments Patient Selection Quality of Life Salvage Therapy Survival Rate *Urinary Bladder Neoplasms/therapy

Antineoplastic Agents Alkylating/pharmacology/*therapeutic use Cyclophosphamide/pharmacology/*therapeutic use Female Humans Male Survival Analysis Urinary Bladder Neoplasms/*drug therapy/mortality Cyclophosphamide Hematuria Systematic review Urinary bladder neoplasms

bladder cancer mediation socioeconomic status survival systematic review Janssen and undertakes research funded by UroGen Pharma and QED Therapeutics. We can confirm all other authors have no conflicts of interest to declare.

Adult Aged Aged 80 and over B7-H1 Antigen/genetics/*immunology Female Humans Immune Checkpoint Inhibitors/*administration & dosage *Immunotherapy Male Middle Aged Programmed Cell Death 1 Receptor/genetics/*immunology Progression-Free Survival Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/genetics/immunology/mortality/*therapy efficacy immunotherapy meta-analysis safety urothelial cancer this study.

Carcinoma Transitional Cell/*mortality/pathology/surgery Cystectomy Disease-Free Survival Humans Neoplasm Recurrence Local/*diagnosis/epidemiology/pathology Prognosis Risk Assessment/methods Urinary Bladder/*pathology/surgery Urinary Bladder Neoplasms/*mortality/pathology/surgery Urothelium/*pathology/surgery histology meta-analysis urinary bladder neoplasms

Chemotherapy Adjuvant *Cystectomy/methods Humans Neoadjuvant Therapy Smoking/*adverse effects Survival Rate Treatment Outcome Urinary Bladder Neoplasms/drug therapy/*mortality/*surgery cigarette smoking cystectomy recurrence survival urinary bladder neoplasms

Biomarkers Tumor/genetics Carcinoma/genetics Gene Expression/genetics Gene Expression Profiling/methods Gene Expression Regulation Neoplastic/genetics Humans Neoplasm Recurrence Local/genetics Odds Ratio Prognosis RNA Circular/*genetics Survival Analysis Transcriptome/genetics Urinary Bladder/pathology Urinary Bladder Neoplasms/*genetics/metabolism bladder cancer circular RNA meta-analysis

*Biomarkers Tumor Carcinoma Transitional Cell/*genetics/mortality/pathology *DNA Methylation Humans Neoplasm Invasiveness Prognosis Risk Assessment Survival Rate Urinary Bladder Neoplasms/*genetics/mortality/pathology Biomarkers Dna High-risk non–muscle-invasive bladder cancer Methylation Prognostic markers Systematic review molecular markers

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant *Cystectomy/methods Humans Neoadjuvant Therapy Neoplasm Invasiveness Survival Rate Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/*surgery Muscle-invasive bladder cancer Neoadjuvant chemotherapy Overall survival Radical cystectomy